Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It is all about time - and where your money does the most work. Currently, we are in a waiting period. Waiting for news of some sort (or in the big picture, waiting for sales/earnings reports). Traders who jumped into the stock are now looking for places they can make money today, not a month or 6 months from now. So if your money in another stock can gain you 5% today, but holding this stock won't get you that gain until later - where are you going to put your money?
Investors hold, traders trade. Only one of those two types are worried about being on the outside if/when good news comes.
Any theories on why its still dropping and possibly how far it will drop?
Long live King Leonidas...
This is what my brokerage says about CHTP (DO NOT SHOOT THE MESSENGER, PLEASE)
Snapshot
Average Target Price: $5 Long Term Growth Rate: NaN%
Year Ago Earnings: $-0.84 Last Quarter's Earnings: $-0.23
P/E on Current Year Estimate $9,999 P/E on Next Fiscal Year Estimate: $9,999
Current Quarters Estimate: -0.21 Current Year's Estimate: -0.83 Next Fiscal Year Estimate: -0.63
Analysts Recommendations - Zacks.com
Str Buy..Mod Buy..Hold..Str Sell.. Mod Sell.. Avg. Recom.
.3......... 1..... 1 .......0........ 0...... Moderate Buy
Analysts Recommendations - MarketWatch.com
Timeframe Mean.... Buy OverWeight Hold UnderWeight Sell Total
Current Overweight. 3..... 0...... 3..... 0......... 0.... 6
1 Wk Ago Overweight 3..... 0...... 3..... 0......... 0.... 6
1 Month Ago Overweight 3.. 0...... 3..... 0..........0.... 6
2 Months Ago Buy...... 5.. 1.......0..... 0......... 0.... 6
Earnings:
Consensus Estimate
Timeframe # of Estimates High Estimate Low Estimate Mean Estimate Coefficient Variance
This Fiscal Year 6 -0.61 -0.95 -0.83 -14.19
Next Fiscal Year 5 -0.3 -1.03 -0.63 -43.39
Last Quarter 1 -0.23 -0.23 -0.2 NaN
This Quarter 5 -0.18 -0.24 -0.21 -10.96
Next Quarter 5 -0.15 -0.22 -0.2 -13.78
I actually doubled up before approval. With a 16-1 advisory vote, I took a chance of full approval. If most of the analysts are correct, should see $10.
Kind of making it hard for investors*. Either way, I doubled down again in hopes for that buyout
Yea it's kind of'l
Cannot agree more! We need more guidance from the company ASAP
Don't get me wrong! We could just as easily be seeing these job postings because they are going to try to launch the product on their own, without partnership/buyout/merger/etc. We should get a little more direction with the conference call next week (I think next week?).
I've got a substantial position in options (relatively speaking) hoping for good news to come out soon...so take what I say with a grain of salt.
They have to keep their choices open. If they don't then they are in a lame duck negotiating position.
Thanks for your answer. It makes me feel much better.
Good eye - those job postings were not there the other day. Even if a buyout or merger is in the works, the company has to protect itself against the idea of such a deal falling through. Collecting these applications could certainly be part of that...
Be careful what you ask for. The way its been trading if we get a
buyout offer its may fall to $4. lol
please give me the name if these companies
Just noticed the company posted three new positions for brand management, market research and national sales. Guess they want to do it by themselves?
A bit surprised this continues to go down, even with $8 to $12 targets from reputable companies...
Smells more and more like dilution especially with the low float...
That's the word in everything I have read for target price of a buyout. So 2+2=4
so you think it will jump to $12 if they announcement buyout?
So easily shaken you are young Jedi. Anybody know anything about mm edgx. Seems they make midpoint plays by the billions so were at the midpoint between 0 and 12/share
Relax ladies and gentlemen, just be patient. CHTP probably had a deal or two in place before the FDA approval. Now that Northera has been approve, the grass has gotten a lot more greener in many different areas. Now there are more then just one or two offers on the table. CHTP has to chose the best deal for all that is involve. That mean "US" the Company, shareholders and investors. Be patient you will see that sold-out, sell out or bought-out, or Merger go cross the screen on the bloomingburg report, CNBC Stocks report, Stocks Report, and ect. By the time you will see it, it will be to late to buy more shares or get in on the sell out.
Just before the FDA approval of Northera, many traders, investors, and long term shareholders sold their shares and moments later the drug was approve, and they couldn't get back in until after the halt was lifted and trading begun, but it was too late to capitalize on the approval, not unless you started shorten the stock. I never have shorten a stock. We're going to get a buyer or merger. And that is not my opinion. But Facts.
you know i'm wondering even if buyout announcement, would the price be worth the time we patience here i don't know but based on what happen after fda approval .. i cant trust any more
Buyout by the end of the week would be awesome... Hopefully when ever the buyout happens the stock reacts a little better than it did after the FDA approval!
I would love for it to be quick myself, but that all depends on the CEO. This guy has got to land a deal and I would this was in talks long ago and simply just waiting for FDA approval, which has been received. I'm calling for buyout end of week.
lool we all know there is buyout coming but the problem or my problem is i need it to be quickly
Oh yes. It's always calm before the storm. There is something brewing alright at CHTP. I just wonder how much is brewing up for each share. $9, 10, 12, or higher. One thing I do know "calm means quiet". Not one word of a buyout can be leak out by CHTP or it's employees. Not even so much as a Press release leaning towards that way of a possible buyout.
I agree and I'm expecting that solid news sometime before March 3rd earnings. I got back in at 5.90 and now buying some 5.60's. This silence is a good thing IMO and indicates some kind of talks happening in the background.
i concur, saw buyout targets of $12, $9, $8. even with the drop I am still in the green, there is no way this is worth less now than it was pre-FDA approval. that would not make any sense. I am holding until we get some solid news
I saw one for 12 w/ buyout somewhere today and 9.)
Still looks to be above the moving average we're still in good shape for upward mobility
price target in nasdaq is $8 and yahoo is $9 can any one help me and give me analysis price from other institutions?
That wasn't my post. I only replied to that persons post. I don't know why his post was deleted though because I too thought it was good unbiased info.
Agreed. If you thought that this stock was worth investing in before the FDA approval, why would you not think it is a good investment after FDA approval? KingDMC - why was your post from Tom Silver deleted? I thought that was good unbiased info.
just news what will rescue us or it will go down day after day ..
i hope after market close we will see something
We found support and are moving back up. No real news triggered this decline -- just a couple people who are easily influenced by the "fear" and "doubt" that articles can portray. All the shares are being picked up by those who aren't worried about a 3-5% intraday swing. Just an opinion.
Exactly why I said we've seen this show. If anything, that's a sign that this screaming buy. Simply another attempt at retail cheapies.
either it's same Friday scenario (stop loss orders) or it's real bad sign ... any way for me i have no idea
SA article came out, which is almost always negative.
What happened!? We were looking good yesterday and now down into the 5.7s WTF!?
Hold tight boys we've seen this show twice. I have strong doubts that this company will go at marketing this drug on their own. No way. Hold right and accumulate.
you are right, CHTP seems to be trading relatively flat. There is no way they spent years researching, developing and going thru trials for this drug only to get a small bump in pps as a result of an FDA approval. there is a deal in the works, we need to be patient.
it's become hard to me day after day ..but i just have feeling that it's impossible to be under $7 at least
Not a problem. Hope they helped.
KingDMC - Thanks for the informative comments you posted by Tom Silver.
Not a problem. Hope it helps.
Looking for buyout announcement this week before March 3 ER. Looking to double down again and extra flip.
Followers
|
82
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
3033
|
Created
|
09/10/07
|
Type
|
Free
|
Moderators |
Chelsea Therapeutics International (NASDAQ: CHTP)
Chelsea Therapeutics International, Ltd., a development stage pharmaceutical company, focuses to acquire and develop products for the treatment of various human diseases. The company develops prescription products for multiple autoimmune disorders, including rheumatoid arthritis, psoriasis, inflammatory bowel disease, and cancer. It also develops therapeutic agent for the treatment of neurogenic orthostatic hypotension and related conditions, and diseases. In addition, the company develops platform technologies that consist of a portfolio of molecules for the treatment of various autoimmune/inflammatory diseases, and I-3D portfolio, a dihydroorotate dehydrogenase inhibiting compound. Chelsea Therapeutics' product in development includes CH-1504, an orally available molecule for the treatment of rheumatoid arthritis, psoriasis, inflammatory bowel disease, psoriatic arthritis, and cancer. The company was incorporated in 2002 and is based in Charlotte, North Carolina.
Chelsea has a balanced portfolio of novel therapeutic agents that address disease states that correspond to significant unmet medical need. Investigational product candidates in the Chelsea pipeline include droxidopa, which is being evaluated for its potential use in indications which we believe norepinephrine may play a role, as well as a library of metabolically inert antifolate medications, including two clinical-stage products, CH-4051 and CH-1504, for the treatment of rheumatoid arthritis and other autoimmune diseases.
Behind these late and mid-stage products is a complementary portfolio of dihydroorotate dehydrogenase (DHODH) inhibitors, known as I-3D, which may have applications in treating autoimmune diseases and transplant rejection.
Chelsea News
News
Facts
The Pipeline
www.chelseatherapeutics.com
http://finance.yahoo.com/q/ks?s=CHTP
Monday, 09/28/2009 - Schedule 13G - http://www.irconnect.com/mc/irc/secfilings.mc?cmd=disp&id=6816624&type=HTML
Tuesday, 09/29/2009 - Schedule 13D - http://www.irconnect.com/mc/irc/secfilings.mc?cmd=disp&id=6818700&type=HTML
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |